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Introduction: The fecal immunochemical test (FIT) has been established as a
cost-effective test in colon cancer screening programmes. This test could also be helpful
in symptomatic patients prior to colonoscopy, but data about diagnostic performance,
and accurate cut-off values for these patients are still scarce.
Materials and Methods: Prospective study that included consecutive unselected
patients with gastrointestinal symptoms referred for colonoscopy between November
2016 and June 2018. We performed a FIT (FOB Gold® test, cut-off 20 micrograms of
Hb/gram of feces) prior to colonoscopy and determined the accuracy of FIT in terms
of sensitivity, specificity, positive and negative predictive value for clinically significant
pathology, advanced neoplasia, and colorectal cancer in symptomatic patients, using
two different cut-off values.
Results: A total of 727 patients (44.3% men, aged 58.5 ± 14.9 years) was included
in the study. The main symptom was history of previous (non-active) rectal bleeding
(34.7%), followed by diarrhea (15.0%). Over one quarter of the patients (25.9%) had a
positive FIT result. The caecal intubation rate was 95.5%. Clinically significant pathology
was identified in 142 colonoscopies (19.5%), advanced neoplasia in 115 (15.8%) and
colorectal cancer in 36 colonoscopies (5.0%). FIT performed very well for clinically
significant pathology, advanced neoplasia and cancer, with a high negative predictive
value (NPV). Reducing the cut-off value to 10µg/g yielded similar NPV results, with a
decrease in specificity. Using a combination of symptoms with a positive FIT result did
not improve FIT performance. Only specificity was slightly higher compared to FIT alone,
but this was paralleled by a decrease in sensitivity and NPV for cancer and clinically
significant pathology. The odds of presenting clinically significant pathology, advanced
neoplasia, or cancer increased with FIT concentration.
Conclusions: The specificity and NPV of FIT for clinically significant pathology,
advanced neoplasia, and cancer are high in symptomatic patients. FIT is a helpful test for
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determining the need to perform further studies. It may not be necessary to reduce the
cut-off value for symptomatic patients, since FIT performance with the current standard
cut-off value used in colorectal cancer screening was accurate. FIT can be used to avoid
or prioritize colonoscopy procedures.
Keywords: colorectal cancer, faecal immunochemical test (FIT), symptomatic patients, cut off value, colonoscopy,
colorectal adenocarcinoma
INTRODUCTION
Colorectal cancer (CRC) is still one of the most commonly
diagnosed cancers around the world, being the second
most prevalent type in women and the third in men (1).
Multiple population-based screening programmes have been
implemented in the past few years, based mostly on the
fecal immunochemical test (FIT) (2, 3), which appears to be
cost-effective compared to non-screening (4, 5).
Gastrointestinal symptoms such as rectal bleeding, change
in bowel habits, diarrhea, or abdominal pain are common
to different gastrointestinal diseases and are considered poor
predictors of the risk of CRC (6). FIT is becoming more widely
used in clinical practice as a diagnostic test for the evaluation of
symptomatic patients before colonoscopy. In the past few years,
several studies (7–10) on the diagnostic accuracy of FIT in this
setting have been published, with promising results, but data are
still scarce.
As FIT is a quantitative test, the cut-off value can be chosen
to adapt each local programme to the availability of endoscopic
resources (11, 12). Some studies suggest that fecal hemoglobin
concentration could be a predictor of risk for advanced neoplasia
and CRC and could be used to prioritize the use of colonoscopy in
symptomatic and asymptomatic patients who have a higher risk
of presenting CRC or advanced neoplasia (13–17).
Along the same line, NICE Guidance (18) and other recent
clinical practice guidelines (19) recommend the use of FIT for
the evaluation of symptomatic patients, but with a cut-off value
lower than that usually used in CRC screening programmes (10
vs. 20µg/g)2. This could result in a higher rate of false positive
tests, with an increase in the demand for colonoscopies, which
could lead to longer waiting times for patients and a potential
negative impact on patients’ prognosis (20, 21).
In this study, we seek to determine the diagnostic performance
of FIT in patients with gastrointestinal symptoms in terms of
sensitivity, specificity, positive and negative predictive value for
CRC, advanced neoplasia, and clinically significant pathology.
MATERIALS AND METHODS
Study Population
This prospective observational study included patients referred
to a general tertiary hospital between November 2016 and June
2018 for colonoscopy due to gastrointestinal symptoms such
as prior history of rectal bleeding, abdominal pain, change in
bowel habits, or diarrhea. We asked these patients to undergo a
fecal immunochemical test prior to starting bowel preparation
for colonoscopy. All patients included in the study signed an
informed consent form, and the study was approved by the
Regional Ethical Committee of Aragón (CEICA).
Patients referred for colonoscopy because of CRC screening
or adenoma follow-up were excluded. Other exclusion criteria
were as follows: presence of comorbidities that contraindicated
the use of colonoscopy, personal history of CRC, colectomy or
a prior diagnosis of inflammatory bowel disease, family history
of at least one first-degree relative diagnosed with CRC or family
history suggesting a hereditary family syndrome.
Positive and negative FIT patients were included in the study.
Fecal Immunochemical Test
Patients were instructed on how to collect a fecal sample
according to the written instructions given with the commercial
kit, which included no medication or dietary restrictions. The
fecal material was collected in a sampling tube and analyzed using
FOB Gold R© (SENTiFIT; Sysmex-Sentinel CH. SpA, Barcelona,
Spain). The cut-off value applied was 117 ng/ml of buffer
(equivalent to 20mg of Hb per gram of feces). For patients
referred due to rectal bleeding, this symptom should have
stopped at least 48 h prior to the performance of the test, which
was assessed by a phone call interview.
Colonoscopy, Histologic Examination, and
Definitions
The colonoscopies were performed by experienced
gastroenterologists from the Digestive Diseases Service of
our center. Any polypoid lesions detected during the procedure
were removed and classified according to the Spanish Network
of Cancer Screening Programmes, based on the European
guidelines for quality assurance in colorectal cancer screening
and diagnosis (22), by an experienced pathologist. Advanced
neoplasia is defined by the European Society of Gastrointestinal
Endoscopy (ESGE) (23) as the presence of colorectal cancer or a
colorectal adenoma with villous histology, high-grade dysplasia,
or ≥10mm in size. Tumor staging was established according to
the TNM classification system of the Union for International
Cancer Control (24). The term “Any lesion” used in this
study refers to the presence of any finding in the colonoscopy
(non-adenomatous polyp, non-advanced adenoma, advanced
adenoma, CRC, inflammatory bowel disease, or vascular
pathology). “Clinically significant pathology” was defined as
the presence of CRC, advanced adenoma, inflammatory bowel
disease, or vascular pathology such as angiodysplasia.
In this study, we considered right-sided lesions to be those
found in the caecum, ascending colon, hepatic flexure, or
transverse colon. Left-sided lesions included those found in the
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sigmoid, descending colon, or splenic flexure. Rectal lesions were
analyzed alone and in combination with left-sided lesions.
Endpoint of the Study
The primary endpoint was to evaluate the diagnostic
performance of the fecal immunochemical test according
to the parameters of sensitivity (Se), specificity (Sp), and
positive and negative predictive values (PPV, NPV) for different
colorectal lesions: CRC, advanced neoplasia (CRC or advanced
adenoma), and clinically significant pathology. The secondary
endpoints were:
- To evaluate the diagnostic performance of FIT using different
cut-off values.
- To evaluate the detection rate of the different lesions
described above.
- To evaluate the diagnostic performance of FIT in combination
with different symptoms.
Statistical Analysis
First, we performed a descriptive analysis of the population
included in the study. Continuous variables were reported as
mean with standard deviation (SD), whereas qualitative variables
were expressed as frequencies and percentages. In order to
evaluate the diagnostic performance of positive FIT alone and
in combination with symptoms, we calculated the sensitivity
(Se), specificity (Sp), positive predictive value (PPV), negative
predictive value (NPV), and diagnostic odds ratio (OR) with
95% confidence intervals (CI) for different colorectal lesions.
Numbers needed to treat (NNT) to detect a CRC, advanced
neoplasia, and clinically significant pathology were calculated.
A logistic regression analysis was performed to determine the
association of FIT quartiles with the detection of advanced
neoplasia and clinically significant pathology, ORs (95%CI)
adjusted by sex and age were reported. We determined positive
FIT using the standard cut-off value (20µg/g) and the cut-off
value suggested in some guidelines (10µg/g). A stratified analysis
according to sex and age was also made; potential interactions
between FIT and demographic variables were assessed by the
correspondingly regression models containing the interaction
term. To compare the diagnostic accuracy between 20 and
10µg/g cut-off, the DTComPair package implemented in R was
used, the McNemar’s test was applied to compare the sensitivities
and specificities, and the generalized score statistic proposed by
Leisenring, Alonzo and Pepe (2000) was applied for evaluating
the differences in (positive and negative) predictive values. A
two-sided p < 0.05 was considered statistically significant. The
statistical analysis was performed using the SPSS software v. 26.0
for Windows (SPSS Ibérica, Madrid, Spain).
Sample Size Calculation
We calculated the sample size for this study based on the results
of a pilot study of the group carried out with 100 patients, which
obtained a CRC prevalence of 8%, and a FIT sensitivity of 100%,
and specificity of 83.7%. A sample size of 633 patients would be
necessary to estimate the sensitivity and specificity of the test with
an accuracy of 3% and a confidence level of 95%.
TABLE 1 | Indications for colonoscopy.
n (%)
Prior history of rectal bleeding 252 (34.7)
Diarrhea 109 (15.0)
Change in bowel habits 108 (14.9)




Constitutional symptoms 14 (1.9)
Total 727 (100.0)
TABLE 2 | Colonoscopy findings.
n (%)
Cancer 36 (5.0)
Advanced adenoma 79 (10.9)
Non-advanced adenoma 66 (9.1)
Non-adenomatous polyp 52 (7.2)
Inflammatory disease 20 (2.8)





Eight-hundred and sixty unselected patients were initially
contacted and 776 eventually participated in the study. Thirty five
patients were additionally excluded due to family history of CRC
whereas other 14 patients had two procedures during the study
period. A total of 727 patients were included in the final analysis.
More women than men participated (55.7% women; 405). The
mean age of patients was 58.5± 14.9 years old, with the youngest
being 18 and the eldest, 89 years old.
The main indication for colonoscopy was a prior history of
rectal bleeding (34.7%), followed by diarrhea (15.0%) (Table 1);
14.6% (106) of patients were taking antiplatelet agents and 3.2%
(23) anticoagulants. Caecal intubation was achieved in 95.5%
(694) of the colonoscopies. The Boston Bowel Preparation Scale
was higher than 6 in 85.2%.
A lesion was found in 35.9% of patients (261/727), there was
clinically significant pathology in 19.5% (142/727) and advanced
neoplasia was found in 15.8% (115/727). Cancer was found in
5.0% of patients (36/727) (Tables 2, 3). The cancer was located
in the rectum in 36.1% (13) of cases, in the left-sided colon in
33.3% (12) and in the right-sided colon in 30.6% (11). 24.35%
(28) of cases of advanced neoplasia were detected in the rectum,
27.8% (32) in the right-sided colon and 47.8% (55) in the left-
sided colon.
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TABLE 3 | Colonoscopy findings, FIT concentration and AUC according to study
definitions.
n (%) FIT value µg/g (Q1-Q3) AUC (95%CI)
Any lesion* 261 (35.9) 18.9 (0.0–219.4) 0.703 (0.661–0.745)
Clinically significant
pathology+
142 (19.5) 84.53 (3.8–1097.7) 0.813 (0.768–0.858)
Neoplasia 182 (25.0) 24.95(0.0–322.5) 0.724 (0.678–0.770)
Advanced neoplasia 115 (15.8) 75.55 (2.9–871.8) 0.791 (0.741–0.841)
Cancer 36 (5.0) 1079.05 (83.5–3178.4) 0.903 (0.848–0.957)
*Any lesion is defined as presence of any finding in the colonoscopy [1 case defined as
others (serrated polyp) is included].
+Clinically significant pathology is defined as presence of CRC, advanced adenoma,
inflammatory bowel disease or vascular pathology [2 cases defined as others (serrated
polyp and rectal ulcer) are included].
Diagnostic Performance of FIT According
to Colonoscopy Findings
FIT was positive in 25.9% of patients (188) using 20µg/g as
the cut-off value. Reducing the cut-off value to 10µg/g, as
suggested in some guidelines, increased the rate to 28.3% (206),
which would have required a 9.6% increase in the number
of colonoscopies (18). Ten of these 18 colonoscopies (55.6%)
would have had a normal result. The other eight procedures
(44.4%) would have had pathological results: five cases of
advanced neoplasia (1 cancer, 4 advanced adenoma), one of
microscopic colitis, one of vascular lesion and one case of non-
advanced adenoma.
Three complications were recorded during the study: two
perforations that required surgery and one case of post-
polypectomy bleeding. FIT was negative (0µg/g) in one of these
cases and positive (≥20µg/g of feces) in the other two.
Fecal hemoglobin concentration value increased as the lesions
detected in the colonoscopies were more severe. The area under
the curve (AUC) of FIT increased parallel to the severity of lesions
(Table 3).
Sensitivity, specificity, PPV, and NPV were calculated for
the different lesions using the standard cut-off value (20µg/g)
used in our area, obtaining a high NPV for cancer as well
as for clinically significant pathology and advanced neoplasia.
The diagnostic performance of FIT was also calculated using
the cut-off value suggested in some guidelines (10µg/g), with
similar results for NPV and higher sensitivity but lower specificity
(Table 4).
Diagnostic Performance of FIT According
to the Location of Colonoscopy Findings
Sensitivity, specificity, PPV, and NPV of FIT were calculated for
advanced neoplasia and cancer according to their location in
the colon using the two different cut-off values. No differences
were observed according to the locations of these lesions and FIT
performed very well, maintaining a high NPV using both cut-
off values, with a slight decrease in specificity using the lowest
value for all locations of lesions (Table 5). After reducing the
cut-off value to ≥10µg/g, the sensitivity of the test for detecting
advanced neoplasia or cancer was similar in the rectum and
right-sided colon, but clearly superior in the left-sided colon as
compared to ≥20 µg/g.
When FIT performance was stratified by sex and age,
FIT performed slightly better in patients under the age
of 60, but with similar figures for both cut-off values
(Supplementary Tables 1, 2).
Diagnostic Performance of FIT in
Combination With Symptoms
Sensitivity, specificity, PPV, and NPV were calculated for FIT in
combination with the main symptom that prompted the demand
for colonoscopy. No combination of symptom plus FIT yielded
better results than FIT alone. An increase in specificity was
obtained with the combination of symptoms and FIT, but with a
profound reduction in sensitivity and negative predictive value,
using the two different cut-off values evaluated in the study
(Tables 6–8). The combination of different symptoms such as
anemia+ rectal bleeding+ FIT or abdominal pain+ diarrhea+
change in bowel habits + FIT did not improve the performance
of FIT alone (data not shown).
Risk Stratitication According to Fecal
Hemoglobin Concentration and NNT
Patients that obtained a positive FIT result were classified in
four groups, according to their fecal hemoglobin concentration.
The risk of presenting advanced neoplasia, clinically significant
pathology, and cancer adjusted by sex and age was calculated
considering Q1 as the reference group. The risk was higher as
the fecal hemoglobin concentration increased (Table 9).
NNTs were also calculated according to the two different cut-
off values. NNTs were similar (3) when considering advanced
neoplasia and clinically significant pathology for both cut-off
values. NNT slightly increased when using to lower cut-off value
(7) for cancer compared to 20µg/g (6) (data not shown).
DISCUSSION
This study has evaluated the performance of FIT in patients with
“red flag” symptoms that could suggest the presence of CRC
or clinically significant pathology. FIT has shown a high NPV,
not only for cancer, where it reached 99.4% [data consistent
with prior studies (7–10)], but also for advanced neoplasia and
clinically significant pathology. These findings should encourage
the use of FIT in symptomatic patients before deciding on the
need to perform an invasive test such as colonoscopy, since
symptoms alone have poor specificity (6). The NPV of FIT
in symptomatic patients may be of particular value compared
to screening in asymptomatic patients, since here we need to
identify patients who have no colonic pathology despite having
abdominal symptoms, which may be useful for prioritizing
colonoscopies when resources are limited, as is the case in most
national public health systems.
In our study, <20% of participants presented clinically
significant pathology. Using FIT in this cohort would potentially
have avoided referral and subsequent invasive investigations in a
high percentage of patients with no or mild pathology. Moreover,
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TABLE 4 | Diagnostic performance of FIT according to different cut-off values.
FIT ≥20 µg/g TP FP TN FN Se (95%CI) Sp (95%CI) PPV (95%CI) NPV (95%CI) OR* (95%CI)
Any Lesion 127 61 405 134 48.7% (42.7–54.7) 86.9% (83.5–89.7) 67.6% (60.6–73.8) 75.1% (71.3–78.6) 5.8 (4.0–8.3)
Clinically significant pathology 97 91 494 45 68.3% (60.3–75.4) 84.4% (81.3–87.2) 51.6% (44.5–58.6) 91.7% (89.0–93.7) 10.7 (7.0–16.4)
Neoplasia 98 90 455 84 53.8% (46.6–60.9) 83.5% (80.1–86.4) 52.1% (45.0–59.2) 84.4% (81.1–87.2) 5.2 (3.6–7.7)
Advanced neoplasia 77 111 501 38 67.0% (57.9–74.9) 81.9% (78.6–84.7) 41.0% (34.2–48.1) 92.9% (90.5–94.8) 8.2 (5.2–12.9)
Cancer 33 155 536 3 91.7% (78.2–97.1) 77.6% (74.3–80.5) 17.6% (12.8–23.6) 99.4% (98.4–99.8) 31.4 (9.5–104.5)
FIT ≥10 µg/g TP FP TN FN Se (95%CI) Sp (95%CI) PPV (95%CI) NPV (95%CI) OR* (95%CI)
Any Lesion 135 71 395 126 51.7% (45.7–57.7) 84.8% (81.2–87.7) 65.5% (58.8–71.7) 75.8% (72.0–79.3) 5.4 (3.8–7.7)
Clinically significant pathology 104 102 483 38 73.2% (65.4–79.8) 82.6% (79.3–85.4) 50.5% (43.7–57.2) 92.7% (90.1–94.6) 11.8 (7.6–18.2)
Neoplasia 104 102 443 78 57.1% (49.9–64.1) 81.3% (77.8–84.3) 50.5% (43.7–57.2) 85.0% (81.7–87.8) 5.0 (3.5–7.4)
Advanced neoplasia 82 124 488 33 71.3% (62.5–78.8) 79.7% (76.4–82.7) 39.8% (33.4–46.6) 93.7% (91.2–95.5) 8.5 (5.4–13.6)
Cancer 34 172 519 2 94.4% (81.9–98.5) 75.1% (71.8–78.2) 16.5% (12.1–22.2) 99.6% (98.6–99.9) 41.7 (9.9–176.5)
p-value+
Any lesion 0.005 0.002 0.081 0.112
Clinically significant pathology 0.008 0.001 0.305 0.021
Neoplasia 0.014 0.001 0.131 0.126
Advanced neoplasia 0.025 <0.001 0.253 0.067
Cancer 0.317 <0.001 0.071 0.350
*OR: risk of presenting the outcome with a positive FIT compared to a negative FIT. Adjusted by sex and age.
+p value refers to the comparison of Se, Sp, PPV and NPV with the two cut-off values for the different outcomes.
Bold values highlight the statistically significant data.
TABLE 5 | Diagnostic performance of FIT according to location and cut-off value.
FIT ≥20 µg/g TP FP TN FN Se (95%CI) Sp (95%CI) PPV (95%CI) NPV (95%CI) OR* (95%CI)
Cancer 33 155 536 3 91.7% (78.2–97.1) 77.6% (74.3–80.5) 17.6% (12.8–23.6) 99.4% (98.4–99.8) 31.4 (9.5–104.5)
Right-sided colon 10 178 538 1 90.9% (62.3–98.4) 75.1% (71.8–78.2) 5.3% (2.9–9.5) 99.8% (99.0–100.0) 22.5 (2.8–179.1)
Left-sided colon 10 178 537 2 83.3% (55.2–95.3) 75.1% (71.8–78.1) 5.3% (2.9–9.5) 99.6% (98.7–99.9) 11.4 (2.5–53.2)
Rectum 13 175 539 0 100.0% (77.2–100.0) 75.5% (72.2–78.5) 6.9% (4.1–11.5) 100.0% (99.3–100.0) –
Left-sided colon + rectum 23 165 537 2 92.0% (75.0–97.8) 76.5% (73.2–79.5) 12.2% (8.3–17.7) 99.6% (98.7–99.9) 31.4 (7.3–135.3)
Advanced neoplasia 77 111 501 38 67.0% (57.9–74.9) 81.9% (78.6–84.7) 41.0% (34.2–48.1) 92.9% (90.5–94.8) 8.2 (5.2–12.9)
Right-sided colon 20 168 527 12 62.5% (45.3–77.1) 75.8% (72.5–78.9) 10.6% (7.0–15.9) 97.8% (96.1–98.7) 4.3 (2.0–9.1)
Left-sided colon 36 152 520 19 65.5% (52.3–76.6) 77.4% (74.1–80.4) 19.1% (14.2–25.4) 96.5% (94.6–97.7) 5.4 (3.0–9.8)
Rectum 21 167 532 7 75.0% (56.6–87.3) 76.1% (72.8–79.1) 11.2% (7.4–16.5) 98.7% (97.3–99.4) 8.4 (3.5–20.3)
Left-sided colon + rectum 57 131 513 26 68.7% (58.1–77.6) 79.7% (76.4–82.6) 30.3% (24.2–37.2) 95.2% (93.0–96.7) 7.5 (4.5–12.6)
FIT ≥10 µg/g TP FP TN FN Se (95%CI) Sp (95%CI) PPV (95%CI) NPV (95%CI) OR* (95%CI)
Cancer 34 172 519 2 94.4% (81.9–98.5) 75.1% (71.8–78.2) 16.5% (12.1–22.2) 99.6% (98.6–99.9) 41.7 (9.9–176.5)
Right-sided colon 10 196 520 1 90.9% (62.3–98.4) 72.6% (69.2–75.8) 4.9% (2.7–8.7) 99.8% (98.9–100.0) 19.3 (2.4–154.1)
Left-sided colon 11 195 520 1 91.7% (64.6–98.5) 72.7% (69.3–75.9) 5.3% (3.0–9.3) 99.8% (98.9–100.0) 21.9 (2.8–172.6)
Rectum 13 193 521 0 100.0% (77.2–100.0) 73.0% (69.6–76.1) 6.3% (3.7–10.5) 100.0% (99.3–100.0) –
Left-sided colon + rectum 24 182 520 1 96.0% (80.5–99.3) 74.1% (70.7–77.2) 11.7% (8.0–16.8) 99.8% (98.9–100.0) 57.0 (7.6–426.9)
Advanced neoplasia 82 124 488 33 71.3% (62.5–78.8) 79.7% (76.4–82.7) 39.8% (33.4–46.6) 93.7% (91.2–95.5) 8.5 (5.4–13.6)
Right-sided colon 20 186 509 12 62.5% (45.3–77.1) 73.2% (69.8–76.4) 9.7% (6.4–14.5) 97.7% (96.0–98.7) 3.7 (1.7–7.8)
Left-sided colon 40 166 506 15 72.7% (59.8–85.7) 75.3% (71.9–78.4) 19.4% (14.6–25.4) 97.1% (95.3–98.2) 6.7 (3.6–12.6)
Rectum 22 184 515 6 78.6% (60.5–89.8) 73.7% (70.3–76.8) 10.7% (7.2–15.6) 98.8% (97.5–99.5) 8.9 (3.5–22.6)
Left-sided colon + rectum 62 144 500 21 74.7% (64.4–82.8) 77.6% (74.3–80.7) 30.1% (24.2–36.7) 96.0% (93.9–97.3) 8.8 (5.1–15.2)
*OR: risk of presenting the outcome with a positive FIT compared to a negative FIT. Adjusted by sex and age.
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TABLE 6 | Diagnostic performance of FIT + symptom for colorectal cancer.
FIT ≥20 µg/g TP FP TN FN Se (95%CI) Sp (95%CI) PPV (95%CI) NPV (95%CI) OR* (95%CI)
FIT 33 155 536 3 91.7% (78.2–97.1) 77.6% (74.3–80.5) 17.6 % (12.8–23.6) 99.4% (98.4–99.8) 31.4 (9.5–104.5)
FIT + Rectal bleeding 15 48 643 21 41.7% (27.1–57.8) 93.1% (90.9–94.7) 23.8% (15.0–35.6) 96.8% (95.2–97.9) 11.4 (5.2–24.9)
FIT + Change in bowel habits 1 14 677 35 2.8% (0.5–14.2) 98.0% (96.6–98.8) 6.7% (1.2–29.8) 95.1% (93.2–96.4) 0.9 (0.1–7.6)
FIT + Diarrhea 0 24 667 36 0.0% (0.0–9.6) 96.5% (94.9–97.7) 0.0% (0.0–13.8) 94.9% (93.0–96.3) –
FIT + Abdominal pain 2 20 671 34 5.6% (1.5–18.1) 97.1% (95.6–98.1) 9.1% (2.5–27.8) 95.2% (93.3–96.5) 1.6 (0.3–7.2)
FIT + Anemia 14 31 660 22 38.9% (24.8–55.1) 95.5% (93.7–96.8) 31.1% (19.5–45.7) 96.8% (95.2–97.9) 9.0 (4.1–20.1)
FIT ≥10 µg/g TP FP TN FN Se (95%CI) Sp (95%CI) PPV (95%CI) NPV (95%CI) OR* (95%CI)
FIT 34 172 519 2 94.4% (81.9–98.5) 75.1% (71.8–78.2) 16.5% (12.1–22.2) 99.6% (98.6–99.9) 41.7 (9.9–176.5)
FIT + Rectal bleeding 15 55 636 21 41.7% (27.1–57.8) 92.0% (89.8–93.8) 21.4% (13.4–32.4) 96.8% (95.2–97.9) 9.2 (4.3–19.9)
FIT + Change in bowel habits 2 19 672 34 5.6% (1.5–18.1) 97.3% (95.7–98.2) 9.5% (2.7–28.9) 95.2% (93.3–96.5) 1.5 (0.3–6.7)
FIT + Diarrhea 0 25 666 36 0.0% (0.0–9.6) 96.4% (94.7–97.5) 0.0% (0.0–13.3) 94.9% (93.0–96.3) –
FIT + Abdominal pain 2 21 670 34 5.6% (1.5–18.1) 97.0% (95.4–98.0) 8.7% (2.4–26.8) 95.2% (93.3–96.5) 1.5 (0.3–6.9)
FIT + Anemia 14 32 659 22 38.9% (24.8–55.1) 95.4% (93.5–96.7) 30.4% (19.1–44.8) 96.8% (95.2–97.9) 8.7 (3.9–19.3)
*OR: risk of presenting CRC with a positive FIT compared to a negative FIT. Adjusted by sex and age.
TABLE 7 | Diagnostic performance of FIT + symptom for advanced neoplasia.
FIT ≥20 µg/g TP FP TN FN Se (95%CI) Sp (95%CI) PPV (95%CI) NPV (95%CI) OR* (95%CI)
FIT 77 111 501 38 67.0% (57.9–74.9) 81.9% (78.6–84.7) 41.0% (34.2–48.1) 92.9% (90.5–94.8) 8.2 (5.2–12.9)
FIT + Rectal bleeding 31 32 580 84 27.0% (19.7–35.7) 94.8% (92.7–96.3) 49.2% (37.3–61.2) 87.3% (84.6–89.7) 7.4 (4.1–13.4)
FIT + Change in bowel habits 5 10 602 110 4.3% (1.9–9.8) 98.4% (97.0–99.1) 33.3% (15.2–58.3) 84.6% (81.7–87.0) 2.0 (0.6–6.4)
FIT + Diarrhea 7 17 595 108 6.1% (3.0–12.0) 97.2% (95.6–98.3) 29.2% (14.9–49.2) 84.6% (81.8–87.1) 2.7 (1.0–7.3)
FIT + Abdominal pain 6 16 596 109 5.2% (2.4–10.9) 97.4% (95.8–98.4) 27.3% (13.2–48.2) 84.5% (81.7–87.0) 1.8 (0.7–5.0)
FIT + Anemia 21 24 588 94 18.3% (12.3–26.3) 96.1% (94.2–97.4) 46.7% (32.9–60.9) 86.2% (83.4–88.6) 3.6 (1.8–6.9)
FIT ≥10 µg/g TP FP TN FN Se (95%CI) Sp (95%CI) PPV (95%CI) NPV (95%CI) OR* (95%CI)
FIT 82 124 488 33 71.3% (62.5–78.8) 79.7% (76.4–82.7) 39.8% (33.4–46.6) 93.7% (91.2–95.5) 8.5 (5.4–13.6)
FIT + Rectal bleeding 33 37 575 82 28.7% (21.2–37.5) 94.0% (91.8–95.6) 47.1% (35.9–58.7) 87.5% (84.8–89.8) 6.7 (3.8–11.7)
FIT + Change in bowel habits 7 14 598 108 6.1% (3.0–12.0) 97.7% (96.2–98.6) 33.3% (17.2–54.6) 84.7% (81.9–87.2) 2.4 (0.9–6.4)
FIT + Diarrhea 7 18 594 108 6.1% (3.0–12.0) 97.1% (95.4–98.1) 28.0% (14.3–47.6) 84.6% (81.8–87.1) 2.1 (0.8–5.5)
FIT + Abdominal pain 6 17 595 109 5.2% (2.4–10.9) 97.2% (95.6–98.3) 26.1% (12.5–46.5) 84.5% (81.7–87.0) 1.8 (0.7–4.8)
FIT + Anemia 21 25 587 94 18.3% (12.3–26.3) 95.9% (94.0–97.2) 45.7% (32.2–59.8) 86.2% (83.4–88.6) 3.4 (1.8–6.6)
*OR: risk of presenting advanced neoplasia with a positive FIT compared to a negative FIT. Adjusted by sex and age.
one of the complications recorded in the study would have
been avoidable, since that patient presented a negative FIT result
(0 µg/g).
FIT has also proven useful for prioritizing colonoscopies
for symptomatic patients with positive results, especially those
with high fecal hemoglobin concentrations in the test, as the
risk of presenting a significant lesion is higher when the FIT
hemoglobin concentration increases, which is consistent with
prior studies (14–17). According to our data, FIT could be useful
in two different ways: on the one hand, for avoiding unnecessary
colonoscopies and potential complications in case of a negative
FIT, which would help to decrease waiting lists, and on the
other, for prioritizing endoscopies for patients with symptoms
and a positive FIT result, especially those with higher fecal
hemoglobin concentrations detected in the test (17). This would
be especially helpful in health systems with a limited capacity for
colonoscopies that are already overloaded with long waiting lists
caused by the growing workload due to the implementation of
CRC screening programmes and open access to primary care.
As more women than men participated in the study,
a stratified analysis by sex and age was performed; FIT
performance was similar according to sex, and only FIT
performed a bit better in patients under 60.
Furthermore, in our study, the performance of FIT was
evaluated using two different cut-off values: the one suggested in
recent guidelines for symptomatic patients (10µg/g) and the one
used in multiple screening programmes worldwide, including
our region (20µg/g). Using the two different cut-off values, a
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TABLE 8 | Diagnostic performance of FIT + symptom for clinically significant pathology.
FIT ≥20 µg/g TP FP TN FN Se (95%CI) Sp (95%CI) PPV (95%CI) NPV (95%CI) OR* (95%CI)
FIT 97 91 494 45 68.3% (60.3–75.4) 84.4% (81.3–87.2) 51.6% (44.5–58.6) 91.7% (89.0–93.7) 10.7 (7.0–16.4)
FIT + Rectal bleeding 40 23 562 102 28.2% (21.4–36.1) 96.1% (94.2–97.4) 63.5% (51.1–74.3) 84.6% (81.7–87.2) 9.9 (5.6–17.6)
FIT + Change in bowel habits 6 9 576 136 4.2% (2.0–8.9) 98.5% (97.1–99.2) 40.0% (19.8–64.3) 80.9% (77.8–83.6) 2.3 (0.8–6.8)
FIT + Diarrhea 11 13 572 131 7.7% (4.4–13.3) 97.8% (96.2–98.7) 45.8% (27.9–64.9) 81.4% (78.3–84.1) 4.3 (1.8–10.4)
FIT + Abdominal pain 7 15 570 135 4.9% (2.4–9.8) 97.4% (95.8–98.4) 31.8% (16.4–52.7) 80.9% (77.8–83.6) 1.8 (0.7–4.6)
FIT + Anemia 23 22 563 119 16.2% (11.0–23.1) 96.2% (94.4–97.5) 51.1% (37.0–65.0) 82.6% (79.5–85.2) 9.7 (2.0–7.0)
FIT ≥10 µg/g TP FP TN FN Se (95%CI) Sp (95%CI) PPV (95%CI) NPV (95%CI) OR* (95%CI)
FIT 104 102 483 38 73.2% (65.4–79.8) 82.6% (79.3–85.4) 50.5% (43.7–57.2) 92.7% (90.1–94.6) 11.8 (7.6–18.2)
FIT + Rectal bleeding 43 27 558 99 30.3% (23.3–38.3) 95.4% (93.4–96.8) 61.4% (49.7–72.0) 84.9% (82.0–87.5) 9.1 (5.3–15.6)
FIT + Change in bowel habits 8 13 572 134 5.6% (3.0–10.7) 97.8% (96.2–98.7) 38.1% (20.8–59.1) 81.0% (78.0–83.7) 2.2 (0.9–5.4)
FIT + Diarrhea 11 14 571 131 7.7% (4.4–13.3) 97.6% (96.0–98.6) 44.0% (26.7–62.9) 81.3% (78.3–84.0) 3.9 (1.6–9.1)
FIT + Abdominal pain 7 16 569 135 4.9% (2.4–9.8) 97.3% (95.6–98.3) 30.4% (15.6–50.9) 80.8% (77.8–83.6) 1.7 (0.7–4.3)
FIT + Anemia 23 23 562 119 16.2% (11.0–23.1) 96.1% (94.2–97.4) 50.0% (36.1–63.9) 82.5% (79.5–85.2) 3.6 (1.9–6.7)
*OR: risk of presenting clinically significant pathology with a positive FIT compared to a negative FIT. Adjusted by sex and age.
similar NPV was obtained, with a decrease in specificity and
a small increase in sensitivity when using the lower cut-off
value. FIT performance was also evaluated for both cut-off values
according to the location of colonoscopy findings, with a similar
outcome. No significant differences in NPV or specificity values
for FIT were observed between left-sided and right-sided lesions
using either cut-off point.
According to our results, it may not be necessary to
reduce the cut-off value used for symptomatic patients, and
the standard value used in the screening programme should
also be sufficient for the evaluation of symptomatic patients.
It seems that reducing the cut-off value would increase the
number of false positive results and consequently the number of
colonoscopies, increasing already long waiting lists without any
significant benefit.
A recent meta-analysis of studies evaluating FIT performance
in CRC screening concludes that the sensitivity and specificity
of detection of neoplastic colonic lesions vary with positive cut-
off values and suggests that the cut-off value could be reduced
at centers with sufficient resources for colonoscopy follow-
up. A 49% increase in positive tests and, therefore, follow-up
colonoscopies would be achieved by using a cut-off value of
<10µg/g rather than <20µg/g, compared to 146% using a cut-
off value >10 and <20µg/g rather than >20µg/g, which are
the references used in our study for symptomatic patients (25).
We are aware that although the performance of FIT with a
cut-off of 20µg/g had optimal outcomes, 45 patients presented
clinically significant pathology in the colonoscopy and were FIT
negative (35 advanced adenoma, 3 cancer, 2 vascular lesion, and
5 inflammatory bowel disease cases). Using the 10µg/g cut-off
value, 38 cases would have been FIT negative and would have
presented clinically significant pathology (31 advanced adenoma,
2 cancer, 1 vascular lesion, and 4 inflammatory bowel disease
cases), 28 of them with a FIT value of 0. Therefore, the difference
between the two cut-off values evaluated (20 and 10µg/g) is just
7 cases (1 cancer, 4 advanced adenoma, 1 inflammatory bowel
TABLE 9 | Risk of presenting clinically significant pathology, advanced neoplasia




Q2 (47–110.6) 0.144 1.9 (0.8–4.5)
Q3 (110.6–1069.4) 0.004 3.6 (1.5–8.6)
Q4 (>1069.4) <0.001 9.6 (3.7–24.9)
Advanced neoplasia
Q1 (<47) Reference
Q2 (47–110.6) 0.087 2.3 (0.9–5.8)
Q3 (110.6–1069.4) 0.030 2.8 (1.1–7.2)
Q4 (>1069.4) 0.001 4.9 (1.9–12.7)
Cancer
Q1 (<47) Reference
Q2 (47–110.6) 0.124 3.8 (0.7–20.2)
Q3 (110.6–1069.4) 0.075 4.5 (0.9–23.7)
Q4 (>1069.4) 0.001 16.3 (3.4–78.5)
Bold values highlight the statistically significant data.
disease, and 1 vascular lesion). The question now may be how
to avoid missing cases (especially cancer) without paying the
price of a higher rate of false positives, longer waiting lists, and
loss of opportunity due to the delayed diagnosis of cancer in
overloaded services. As FIT has the strength of being a user-
friendly test, for symptomatic patients with a FIT value between
10 and 20µg/g, repeating the test before deciding on the need
for an invasive procedure would be an option, though more
studies are needed prior making a recommendation. Another
option could be combining FIT with another non-invasive test,
such as calprotectin. In this line a recent study (26) showed
the combination of FIT and fecal calprotectin as a cost-effective
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strategy to avoid colonoscopies in symptomatic patients without
relevant pathology, but further research is needed in this field.
Meanwhile, when suspicion of clinically significant pathology is
high, even with a negative FIT result, a colonoscopy or other
studies should be considered.
Finally, our study has also evaluated the performance of FIT
combined with different symptoms, using the two different cut-
off values. When FIT was combined with symptoms, we obtained
a slight increase in specificity but a decrease in sensitivity and
NPV with both cut-off points. According to our results, FIT
alone, without taking into account the symptom that motivated
the performance of the test, would be enough to decide on the
need to perform subsequent invasive tests such as colonoscopy.
We are aware our study has limitations like the sample
size, specially when symptoms are taken into account, since the
subgroup of patients who meet these conditions is small in some
cases, new studies with a larger sample size would be helpful to
confirm our results.
CONCLUSIONS
The specificity and NPV of FIT for clinically significant
pathology, advanced neoplasia, and cancer are high in
symptomatic patients. FIT is a helpful test for determining
the need to perform further studies without taking symptoms
into account. Reducing the cut-off value below 20 µg of Hb/g of
feces for symptomatic patients may not be necessary in health
systems with a limited capacity for follow-up endoscopies, since
the performance of FIT using the standard cut-off value offers
almost identical NPV. FIT can be used to avoid or prioritize
colonoscopy procedures.
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